Literature DB >> 26034301

Culturing primary mouse pancreatic ductal cells.

Maximilian Reichert1, Andrew D Rhim2, Anil K Rustgi1.   

Abstract

The most common subtype of pancreatic cancer is pancreatic ductal adenocarcinoma (PDAC). PDAC resembles ductal cells morphologically. To study pancreatic ductal cell (PDC) and pancreatic intraepithelial neoplasia (PanIN)/PDAC biology, it is essential to have reliable in vitro culture conditions. Here we describe a methodology to isolate, culture, and passage PDCs and duct-like cells from the mouse pancreas. It can be used to isolate cells from genetically engineered mouse models (GEMMs), providing a valuable tool to study disease models in vitro to complement in vivo findings. The culture conditions allow epithelial cells to outgrow fibroblast and other "contaminating" cell types within a few passages. However, the resulting cultures, although mostly epithelial, are not completely devoid of fibroblasts. Regardless, this protocol provides guidelines for a robust in vitro culture system to isolate, maintain, and expand primary pancreatic ductal epithelial cells. It can be applied to virtually all GEMMs of pancreatic disease and other diseases and cancers that arise from ductal structures. Because most carcinomas resemble ductal structures, this protocol has utility in the study of other cancers in addition to PDAC, such as breast and prostate cancers.
© 2015 Cold Spring Harbor Laboratory Press.

Entities:  

Mesh:

Year:  2015        PMID: 26034301     DOI: 10.1101/pdb.prot078279

Source DB:  PubMed          Journal:  Cold Spring Harb Protoc        ISSN: 1559-6095


  7 in total

1.  Development of a polarized pancreatic ductular cell epithelium for physiological studies.

Authors:  Yunxia O'Malley; Pavana G Rotti; Ian M Thornell; Oriana G Vanegas Calderón; Christopher Febres-Aldana; Katelin Durham; Jianrong Yao; Xiaopeng Li; Zheng Zhu; Andrew W Norris; Joseph Zabner; John F Engelhardt; Aliye Uc
Journal:  J Appl Physiol (1985)       Date:  2018-03-08

2.  Dinaciclib prolongs survival in the LSL-KrasG12D/+ ; LSL-Trp53R172H/+ ; Pdx-1-Cre (KPC) transgenic murine models of pancreatic ductal adenocarcinoma.

Authors:  Jia Yang; Su Hu; Junjie Shangguan; Aydin Eresen; Yu Li; Quanhong Ma; Vahid Yaghmai; Al B Benson Iii; Zhuoli Zhang
Journal:  Am J Transl Res       Date:  2020-03-15       Impact factor: 4.060

3.  Establishment and Characterization of Immortalized Miniature Pig Pancreatic Cell Lines Expressing Oncogenic K-RasG12D.

Authors:  Hae-Jun Yang; Bong-Seok Song; Bo-Woong Sim; Yena Jung; Unbin Chae; Dong Gil Lee; Jae-Jin Cha; Seo-Jong Baek; Kyung Seob Lim; Won Seok Choi; Hwal-Yong Lee; Hee-Chang Son; Sung-Hyun Park; Kang-Jin Jeong; Philyong Kang; Seung Ho Baek; Bon-Sang Koo; Han-Na Kim; Yeung Bae Jin; Young-Ho Park; Young-Kug Choo; Sun-Uk Kim
Journal:  Int J Mol Sci       Date:  2020-11-21       Impact factor: 5.923

Review 4.  Gastrointestinal Organoids: Understanding the Molecular Basis of the Host-Microbe Interface.

Authors:  David R Hill; Jason R Spence
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2016-12-19

5.  Mir34a constrains pancreatic carcinogenesis.

Authors:  Ana Hidalgo-Sastre; Clara Lubeseder-Martellato; Thomas Engleitner; Katja Steiger; Suyang Zhong; Judit Desztics; Rupert Öllinger; Roland Rad; Roland M Schmid; Heiko Hermeking; Jens T Siveke; Guido von Figura
Journal:  Sci Rep       Date:  2020-06-15       Impact factor: 4.379

6.  An improved method for the isolation and culture of rat pancreatic ductal epithelial cells.

Authors:  Renjie Chang; Heping Qin; Zhihai Liang; Mengbin Qin; Huilin Wang; Yule Wei; Hongzong Fu; Huali Huang; Guodu Tang
Journal:  Ann Transl Med       Date:  2020-03

7.  Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer.

Authors:  Kanchan Singh; Melissa Pruski; Rachael Bland; Mamoun Younes; Sushovan Guha; Nirav Thosani; Anirban Maitra; Brooks D Cash; Florencia McAllister; Craig D Logsdon; Jeffrey T Chang; Jennifer M Bailey-Lundberg
Journal:  Lab Invest       Date:  2020-10-02       Impact factor: 5.662

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.